Poseida Therapeutics Inc (PSTX) USD0.0001
$0.01
(0.11%)
- Add to watchlist
- This stock can be held in a
$0.01
(0.11%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$0.01
(0.11%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.
Contact details
Important dates
General stock information
- Short code:
- PSTX
- ISIN:
- US73730P1084
- Market cap:
- $924.96 million
- Shares in issue:
- 97.47 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- NASDAQ Comb. Composite
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.